MA54009B1 - Formulation d'afabicine et son procédé de préparation - Google Patents
Formulation d'afabicine et son procédé de préparationInfo
- Publication number
- MA54009B1 MA54009B1 MA54009A MA54009A MA54009B1 MA 54009 B1 MA54009 B1 MA 54009B1 MA 54009 A MA54009 A MA 54009A MA 54009 A MA54009 A MA 54009A MA 54009 B1 MA54009 B1 MA 54009B1
- Authority
- MA
- Morocco
- Prior art keywords
- afabicin
- formulation
- preparation
- compositions
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques solides contenant de l'afabicine présentant des caractéristiques supérieures de dissolution. Cet effet bénéfique est accompli par la présence d'un composé histidine pour la fabrication des compositions. La présente invention concerne en outre des procédés de préparation de telles compositions et des utilisations associées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157255 | 2019-02-14 | ||
PCT/EP2020/053882 WO2020165407A1 (fr) | 2019-02-14 | 2020-02-14 | Formulation d'afabicine et son procédé de préparation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA54009A1 MA54009A1 (fr) | 2022-05-31 |
MA54009B1 true MA54009B1 (fr) | 2022-10-31 |
Family
ID=65440901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA54009A MA54009B1 (fr) | 2019-02-14 | 2020-02-14 | Formulation d'afabicine et son procédé de préparation |
Country Status (28)
Country | Link |
---|---|
US (1) | US20220142993A1 (fr) |
EP (1) | EP3923914B1 (fr) |
JP (1) | JP7383715B2 (fr) |
KR (1) | KR20210127187A (fr) |
CN (2) | CN116327781A (fr) |
AU (1) | AU2020223515A1 (fr) |
BR (1) | BR112021015825B1 (fr) |
CA (1) | CA3129508A1 (fr) |
CL (1) | CL2021002149A1 (fr) |
CY (1) | CY1126077T1 (fr) |
DK (1) | DK3923914T3 (fr) |
EA (1) | EA202192246A1 (fr) |
ES (1) | ES2944535T3 (fr) |
FI (1) | FI3923914T3 (fr) |
HR (1) | HRP20230437T1 (fr) |
HU (1) | HUE062061T2 (fr) |
IL (1) | IL285204A (fr) |
LT (1) | LT3923914T (fr) |
MA (1) | MA54009B1 (fr) |
MX (1) | MX2021009799A (fr) |
PL (1) | PL3923914T3 (fr) |
PT (1) | PT3923914T (fr) |
RS (1) | RS64158B1 (fr) |
SG (1) | SG11202108591PA (fr) |
SI (1) | SI3923914T1 (fr) |
TN (1) | TN2021000159A1 (fr) |
UA (1) | UA128316C2 (fr) |
WO (1) | WO2020165407A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021007219A (es) | 2018-12-21 | 2021-09-23 | Acurx Pharmaceuticals Llc | Inhibidores de la adn polimerasa iiic y sus usos. |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002367773A1 (en) | 2001-04-06 | 2003-11-03 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
CN101415701A (zh) * | 2005-12-05 | 2009-04-22 | Affinium医药公司 | 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂 |
EP2125802A4 (fr) * | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | Sels, promédicaments et polymorphes d'inhibiteurs de fab 1 |
RS58898B1 (sr) | 2012-06-19 | 2019-08-30 | Debiopharm Int Sa | Prolek derivati (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida |
LT3419628T (lt) | 2016-02-26 | 2021-01-25 | Debiopharm International Sa | Medikamentas diabetinėms pėdų infekcijoms gydyti |
-
2020
- 2020-02-14 AU AU2020223515A patent/AU2020223515A1/en active Pending
- 2020-02-14 HU HUE20704307A patent/HUE062061T2/hu unknown
- 2020-02-14 CA CA3129508A patent/CA3129508A1/fr active Pending
- 2020-02-14 MA MA54009A patent/MA54009B1/fr unknown
- 2020-02-14 FI FIEP20704307.6T patent/FI3923914T3/fi active
- 2020-02-14 CN CN202310544746.8A patent/CN116327781A/zh active Pending
- 2020-02-14 JP JP2021545458A patent/JP7383715B2/ja active Active
- 2020-02-14 WO PCT/EP2020/053882 patent/WO2020165407A1/fr active Application Filing
- 2020-02-14 MX MX2021009799A patent/MX2021009799A/es unknown
- 2020-02-14 ES ES20704307T patent/ES2944535T3/es active Active
- 2020-02-14 TN TNP/2021/000159A patent/TN2021000159A1/en unknown
- 2020-02-14 UA UAA202105153A patent/UA128316C2/uk unknown
- 2020-02-14 LT LTEPPCT/EP2020/053882T patent/LT3923914T/lt unknown
- 2020-02-14 EA EA202192246A patent/EA202192246A1/ru unknown
- 2020-02-14 PT PT207043076T patent/PT3923914T/pt unknown
- 2020-02-14 RS RS20230315A patent/RS64158B1/sr unknown
- 2020-02-14 PL PL20704307.6T patent/PL3923914T3/pl unknown
- 2020-02-14 SG SG11202108591PA patent/SG11202108591PA/en unknown
- 2020-02-14 EP EP20704307.6A patent/EP3923914B1/fr active Active
- 2020-02-14 US US17/430,616 patent/US20220142993A1/en active Pending
- 2020-02-14 KR KR1020217028702A patent/KR20210127187A/ko unknown
- 2020-02-14 SI SI202030183T patent/SI3923914T1/sl unknown
- 2020-02-14 CN CN202080014005.3A patent/CN113423390B/zh active Active
- 2020-02-14 BR BR112021015825-1A patent/BR112021015825B1/pt active IP Right Grant
- 2020-02-14 HR HRP20230437TT patent/HRP20230437T1/hr unknown
- 2020-02-14 DK DK20704307.6T patent/DK3923914T3/da active
-
2021
- 2021-07-28 IL IL285204A patent/IL285204A/en unknown
- 2021-08-13 CL CL2021002149A patent/CL2021002149A1/es unknown
-
2023
- 2023-05-09 CY CY20231100220T patent/CY1126077T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202108591PA (en) | 2021-09-29 |
BR112021015825A2 (pt) | 2021-10-13 |
WO2020165407A1 (fr) | 2020-08-20 |
EP3923914B1 (fr) | 2023-04-12 |
MA54009A1 (fr) | 2022-05-31 |
CN116327781A (zh) | 2023-06-27 |
UA128316C2 (uk) | 2024-06-05 |
AU2020223515A1 (en) | 2021-08-19 |
SI3923914T1 (sl) | 2023-08-31 |
CN113423390B (zh) | 2023-05-23 |
US20220142993A1 (en) | 2022-05-12 |
JP7383715B2 (ja) | 2023-11-20 |
TN2021000159A1 (en) | 2023-04-04 |
CL2021002149A1 (es) | 2022-03-04 |
CY1126077T1 (el) | 2023-11-15 |
DK3923914T3 (da) | 2023-05-01 |
RS64158B1 (sr) | 2023-05-31 |
PL3923914T3 (pl) | 2023-08-07 |
CN113423390A (zh) | 2021-09-21 |
HRP20230437T1 (hr) | 2023-07-07 |
CA3129508A1 (fr) | 2020-08-20 |
BR112021015825B1 (pt) | 2024-03-12 |
FI3923914T3 (fi) | 2023-04-27 |
HUE062061T2 (hu) | 2023-09-28 |
EP3923914A1 (fr) | 2021-12-22 |
KR20210127187A (ko) | 2021-10-21 |
MX2021009799A (es) | 2021-09-08 |
ES2944535T3 (es) | 2023-06-22 |
IL285204A (en) | 2021-09-30 |
LT3923914T (lt) | 2023-07-25 |
PT3923914T (pt) | 2023-05-04 |
EA202192246A1 (ru) | 2021-11-18 |
JP2022520170A (ja) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54009B1 (fr) | Formulation d'afabicine et son procédé de préparation | |
MA58004B1 (fr) | Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
FR2525205A1 (fr) | Composition biocide a base d'isothiazolone et de glutaraldehyde et procede pour le traitement d'eau de refroidissement ou d'eau utilisee dans la fabrication du papier | |
MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
FR3086943B1 (fr) | Copolymere d'ethylene et de beta-farnesene | |
MA31684B1 (fr) | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation | |
WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
MA53189B2 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
MA29950B1 (fr) | Nouveau derive de la pleuromutiline et son utilisation | |
MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
FR3100723B1 (fr) | Procédé de préparation d’atomes métalliques isolés ou d’un mélange d’atomes métalliques isolés et de nanoparticules métalliques sur matériau carboné | |
MA51664B1 (fr) | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide | |
CA2473203A1 (fr) | Composition pharmaceutique orodispersible d'ivabradine | |
FR3105788B1 (fr) | Procede de preparation de particules enrobees d’oxyde de silicium par pyrolyse par projection de flamme | |
FR3105787B1 (fr) | Procede de preparation de particules d’oxyde de zinc enrobees par pyrolyse par projection de flamme | |
FR2401132A1 (fr) | Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant | |
HUP0401405A2 (hu) | Xa faktor inhibitor tulajdonságú fenilszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
FR3105976B1 (fr) | Composition de matière et procédé de préparation de celle-ci | |
KR950003282A (ko) | 살균성 스피로헤테로시클릭 화합물 및 이들의 제조방법 | |
CA3156074A1 (fr) | Inhibiteurs de mll1 et agents anticancereux | |
US2614918A (en) | Method of setting fruit and composition therefor | |
US2411443A (en) | Manufacture of soap | |
FR2403798A1 (fr) | Compositions synergiques a base de disulfure de bis(2-pyridyl-1-oxyde et leur utilisation pour leur activite anti-inflammatoire |